Close Menu

NEW YORK – The US Food and Drug Administration has granted AstraZeneca and Daiichi Sankyo's fam-trastuzumab deruxtecan-nxki (Enhertu) breakthrough therapy designation as a treatment for HER2-mutated, metastatic non-small cell lung cancer that has progressed after platinum-based therapy. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
27
Sponsored by
Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments.